BioCentury | Apr 9, 2021
Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello

...gene therapies.Cleave’s small molecule therapy to treat AMLINSERM and Harvard Medical School researchers characterized a VCP...
...anthracycline and antimetabolite. The work is published in Science Translational Medicine. Cleave Therapeutics Inc. is developing VCP...
BioCentury | Aug 7, 2019
Financial News

VCs recapitalize Cleave around next-gen molecule

...its inception in 2011. By the time of its 2016 series B round, its first-in-class VCP...
...Burroughs. Fortunately for Cleave Therapeutics Inc. (San Francisco, Calif.), the National Cancer Institute's enthusiasm for VCP...
...rights in oncology. Targets: PDE-6 - Phosphodiesterase-6; VCP (p97) - Valosin containing protein Paul Bonanos, Associate Editor CB-5083 Cleave Therapeutics Inc. Valosin containing protein (VCP) (p97) CB-5339 Cleave...
BioCentury | Aug 23, 2018
Distillery Therapeutics

Infectious

INDICATION: HIV/AIDS Primate studies suggest combining CD4 mimetics with HIV gp120-based vaccines could help prevent HIV. In macaques challenged with simian human immunodeficiency virus (SHIV) immunized with HIV gp120 variants, a CD4 mimetic prevented infection...
BioCentury | Dec 6, 2017
Preclinical News

Cancer target of alcohol abuse drug disulfiram identified

...valosin containing protein (VCP, p97) segregase complex, which facilitates protein degradation. Sequestration of NPLOC4 with disulfiram inhibited VCP-dependent...
...also proposes monitoring accumulation of NPLOC4 in cancer tissue as a biomarker for disulfiram responders. Allison Johnson Valosin containing protein (VCP) (p97) Palacky...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Macaque studies suggest adding a boost containing five HIV gp120 variants to HIV vaccine regimens could help prevent infection by the virus. The boost consists of the adjuvant GLA-SE and five...
BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

...the expression of PYDC2 could help treat bacterial infections. Albany Medical College Distillery Therapeutics Clostridium Valosin containing protein...
BioCentury | Jun 20, 2017
Distillery Therapeutics

Infectious disease

...Weissman, same affiliation as above email: weissmaa@mail.nih.gov Julian Zhu Johns Hopkins University National Cancer Institute C. botulinum toxin type A SNAP-25 Valosin containing protein...
BioCentury | Apr 28, 2017
Finance

1Q17 public-private partnership roundup

This quarter’s deal-making in public-private partnerships (PPPs) picked up from the slow rate in the second half of last year, with 1Q17 activity comparable to that seen at the start of last year. Led by...
BioCentury | Feb 28, 2017
Clinical News

Caltech group finds proteasome inhibitor with novel MOA

...Cleave is in Phase I with a new class of compounds that target valosin containing protein (VCP; p97...
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: Valosin containing protein (VCP; p97); huntingtin (HTT)

...inhibitor of VCP could help treat HD. In postmortem caudate nuclear tissue samples, levels of VCP...
...synthetic, cell-penetrating peptide containing a VCP homology sequence inhibited the interaction between mutant HTT and VCP...
...inhibitor and testing it in other diseases involving genes with polyglutamine repeats. TARGET/MARKER/PATHWAY: Valosin containing protein (VCP; p97...
Items per page:
1 - 10 of 50